Visibility of prostate cancer on transrectal ultrasound during fusion with multi-parametric magnetic resonance imaging for biopsy

W. van de Ven, J. Sedelaar, M. van der Leest, C. de Hulsbergen-van Kaa, J. Barentsz, J. Futterer and H. Huisman

Clinical Imaging 2016;40(4):745-750.

DOI PMID Cited by ~21


To determine TRUS visibility of MR lesions.


Data from 34 patients with 56 MR lesions and prostatectomy was used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to PIRADS and Gleason scores.


TRUS visibility occurred in 43% of all MR lesions and 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS visible lesions had a Gleason 4 or 5 component.


Almost half of the MR lesions were visible on TRUS. TRUS visible lesions were more aggressive than TRUS invisible lesions.